arrow
M

Mithun Vinod Shah

Mayo Clinic
H指数:35
被引数:4,587

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Prognostic impact of need for re-induction based on day-14 residual disease and age-adapted consolidation strategy in acute myeloid leukemia

基于第14天残留病灶和年龄适应巩固策略的再诱导需求对急性髓系白血病预后的影响

2026-09-300
OAAI
Clinical and molecular characteristics of clonal monocytosis with and without cytopenia(s)

克隆性单核细胞增多症的临床和分子特征:伴有与不伴有血细胞减少(症)的比较

Leukemia
IF13.4
2026-09-280
PRE
Venetoclax Plus Hypomethylating Agent for 7- Versus 14- Versus 21- Versus 28-Day Cycles in Newly-Diagnosed Acute Myeloid Leukemia: ELN and Mayo Genetic Risk–Stratified Analysis in 540 Patients

维奈克拉联合去甲基化药物用于新诊断急性髓系白血病7天、14天、21天及28天疗程:基于ELN和Mayo遗传风险分层的540例患者分析

2026-09-180
PRE
Coronary Artery Calcification as a Predictor of Survival in Patients Receiving Post-transplant Cyclophosphamide for GVHD Prophylaxis

冠状动脉钙化作为接受移植后环磷酰胺预防GVHD患者的生存预测因子

2026-09-012
OAAI
Determinants of survival after failure of frontline venetoclax plus hypomethylating agent therapy in 356 patients with newly diagnosed acute myeloid leukemia

356例新诊断急性髓系白血病患者一线维奈克拉联合去甲基化药物治疗失败后的生存影响因素

2026-08-170
OAAI
Risk-Adjusted Comparison of Survival in Chronic Myelomonocytic Leukemia With and Without Allogeneic Stem Cell Transplant: Mayo Clinic Experience in 775 Consecutive Patients

慢性髓系单核细胞白血病患者行异基因干细胞移植与未移植者的风险调整生存比较:梅奥诊所775例连续患者的经验

2026-07-280
PRE
Characteristics and outcomes of secondary hematological malignancies following autologous stem cell transplantation for multiple myeloma

自体干细胞移植治疗多发性骨髓瘤后继发血液系统恶性肿瘤的特征与结局

2026-06-230
OAAI
Mutational Profiling Links Biologically Relevant Variants to Multi-Systemic Rosai-Dorfman Disease

突变谱分析将生物学相关的变异与多系统性罗西-道夫曼病联系起来

2026-05-220
OAAI
Characteristics of patients with newly diagnosed acute myeloid leukemia not receiving treatment

新诊断急性髓系白血病未接受治疗患者的特征

2026-01-010
OA
Clinical and Prognostic Impact of Allelic Status in EZH2-Mutated Myeloid Neoplasms

EZH2突变髓系肿瘤中等位基因状态的临床及预后影响

2025-10-230
PRE
Allogeneic stem cell transplantation in chronic myelomonocytic leukemia: analysis of post-transplant survival and risk factors in 138 Mayo Clinic patients

异基因干细胞移植在慢性髓单核细胞白血病中的应用:对138例梅奥诊所患者移植后生存及危险因素的分析

2025-10-060
OA
Applicability of current prognostication models for MDS patients with DDX41 mutation

DDX41突变伴发MDS患者现有预后模型的适用性

2025-10-010
PRE
Risk of Relapse Post Reduced Intensity Conditioning Allogeneic Stem Cell Transplant in Patients With High-Risk Myeloid Neoplasms Based on GvHD Prophylaxis: PTCy Vs. TAC/MTX

基于移植物抗宿主病预防的减低强度预处理异基因造血干细胞移植后高风险髓系肿瘤患者的复发风险:PTCy与TAC/MTX的比较

2025-09-040
OAAI
Cardiovascular Degeneration in Erdheim-Chester Disease: Prevalence, Burden, and Outcomes

Erdheim-Chester 病中的心血管退行性变:患病率、负担和结局

2025-09-030
OAAI
Outcomes of Post-Transplant Rh-GCSF and Decitabine Maintenance Therapy in Patients With High-Risk Myeloid Neoplasm

移植后重组人粒细胞集落刺激因子和地西他滨维持治疗在高风险髓系肿瘤患者中的疗效

2025-07-290
OAAI
RAS mutation identifies a poor prognostic molecular subtype of therapy-related myeloid neoplasm

RAS突变识别出治疗相关性髓系肿瘤的不良预后分子亚型

2025-05-260
OA